🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to health experts.

An International Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting in excess of 82 million instances per year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, escalating drug resistance and the very limited available drugs presently on offer.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This authorization signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which combines a dual-drug approach. The research included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in many developing nations.

Medical professionals on the front lines have voiced optimism. The availability of a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed essential to lessen the impact of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.